Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Total Liabilities (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Total Liabilities for 13 consecutive years, with $11.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 20.52% to $11.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.1 million, a 20.52% decrease, with the full-year FY2025 number at $11.1 million, down 20.52% from a year prior.
  • Total Liabilities was $11.1 million for Q4 2025 at Ekso Bionics Holdings, down from $12.0 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $16.3 million in Q4 2023 to a low of $8.8 million in Q2 2022.
  • A 5-year average of $13.5 million and a median of $14.1 million in 2024 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: surged 45889.29% in 2021, then tumbled 31.73% in 2022.
  • Ekso Bionics Holdings' Total Liabilities stood at $11.9 million in 2021, then increased by 29.41% to $15.5 million in 2022, then increased by 5.5% to $16.3 million in 2023, then decreased by 14.51% to $13.9 million in 2024, then fell by 20.52% to $11.1 million in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Total Liabilities are $11.1 million (Q4 2025), $12.0 million (Q3 2025), and $12.2 million (Q2 2025).